FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953682493> ?p ?o ?g. }

• W2953682493 endingPage "98" @default.
• W2953682493 startingPage "91" @default.
• W2953682493 abstract "Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results.We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria.The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33).The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity.ClinicalTrial.Gov NCT00545077 and NCT00601900." @default.
• W2953682493 created "2019-07-12" @default.
• W2953682493 creator A5004169289 @default.
• W2953682493 creator A5012979471 @default.
• W2953682493 creator A5026324971 @default.
• W2953682493 creator A5029469753 @default.
• W2953682493 creator A5035054317 @default.
• W2953682493 creator A5039694693 @default.
• W2953682493 creator A5039927103 @default.
• W2953682493 creator A5040331693 @default.
• W2953682493 creator A5043393829 @default.
• W2953682493 creator A5047713528 @default.
• W2953682493 creator A5052268581 @default.
• W2953682493 creator A5059070824 @default.
• W2953682493 creator A5061721402 @default.
• W2953682493 creator A5065395756 @default.
• W2953682493 creator A5069795948 @default.
• W2953682493 creator A5070245248 @default.
• W2953682493 creator A5070416057 @default.
• W2953682493 creator A5071909800 @default.
• W2953682493 creator A5075662505 @default.
• W2953682493 creator A5077307794 @default.
• W2953682493 creator A5085083246 @default.
• W2953682493 creator A5087559224 @default.
• W2953682493 date "2019-08-01" @default.
• W2953682493 modified "2023-10-18" @default.
• W2953682493 title "Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials" @default.
• W2953682493 cites W1966392018 @default.
• W2953682493 cites W1976585485 @default.
• W2953682493 cites W2012658469 @default.
• W2953682493 cites W2021777913 @default.
• W2953682493 cites W2076820945 @default.
• W2953682493 cites W2098516378 @default.
• W2953682493 cites W2099824657 @default.
• W2953682493 cites W2101063853 @default.
• W2953682493 cites W2103563357 @default.
• W2953682493 cites W2114426106 @default.
• W2953682493 cites W2126275851 @default.
• W2953682493 cites W2144915560 @default.
• W2953682493 cites W2153982924 @default.
• W2953682493 cites W2167224460 @default.
• W2953682493 cites W2346624277 @default.
• W2953682493 cites W2620080766 @default.
• W2953682493 doi "https://doi.org/10.1016/j.ejca.2019.06.002" @default.
• W2953682493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6718694" @default.
• W2953682493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31276981" @default.
• W2953682493 hasPublicationYear "2019" @default.
• W2953682493 type Work @default.
• W2953682493 sameAs 2953682493 @default.
• W2953682493 citedByCount "15" @default.
• W2953682493 countsByYear W29536824932020 @default.
• W2953682493 countsByYear W29536824932021 @default.
• W2953682493 countsByYear W29536824932022 @default.
• W2953682493 countsByYear W29536824932023 @default.
• W2953682493 crossrefType "journal-article" @default.
• W2953682493 hasAuthorship W2953682493A5004169289 @default.
• W2953682493 hasAuthorship W2953682493A5012979471 @default.
• W2953682493 hasAuthorship W2953682493A5026324971 @default.
• W2953682493 hasAuthorship W2953682493A5029469753 @default.
• W2953682493 hasAuthorship W2953682493A5035054317 @default.
• W2953682493 hasAuthorship W2953682493A5039694693 @default.
• W2953682493 hasAuthorship W2953682493A5039927103 @default.
• W2953682493 hasAuthorship W2953682493A5040331693 @default.
• W2953682493 hasAuthorship W2953682493A5043393829 @default.
• W2953682493 hasAuthorship W2953682493A5047713528 @default.
• W2953682493 hasAuthorship W2953682493A5052268581 @default.
• W2953682493 hasAuthorship W2953682493A5059070824 @default.
• W2953682493 hasAuthorship W2953682493A5061721402 @default.
• W2953682493 hasAuthorship W2953682493A5065395756 @default.
• W2953682493 hasAuthorship W2953682493A5069795948 @default.
• W2953682493 hasAuthorship W2953682493A5070245248 @default.
• W2953682493 hasAuthorship W2953682493A5070416057 @default.
• W2953682493 hasAuthorship W2953682493A5071909800 @default.
• W2953682493 hasAuthorship W2953682493A5075662505 @default.
• W2953682493 hasAuthorship W2953682493A5077307794 @default.
• W2953682493 hasAuthorship W2953682493A5085083246 @default.
• W2953682493 hasAuthorship W2953682493A5087559224 @default.
• W2953682493 hasBestOaLocation W29536824931 @default.
• W2953682493 hasConcept C121608353 @default.
• W2953682493 hasConcept C126322002 @default.
• W2953682493 hasConcept C143998085 @default.
• W2953682493 hasConcept C168563851 @default.
• W2953682493 hasConcept C203092338 @default.
• W2953682493 hasConcept C207103383 @default.
• W2953682493 hasConcept C2775930923 @default.
• W2953682493 hasConcept C2776694085 @default.
• W2953682493 hasConcept C2777802072 @default.
• W2953682493 hasConcept C2780739268 @default.
• W2953682493 hasConcept C44249647 @default.
• W2953682493 hasConcept C530470458 @default.
• W2953682493 hasConcept C71924100 @default.
• W2953682493 hasConcept C90924648 @default.
• W2953682493 hasConceptScore W2953682493C121608353 @default.
• W2953682493 hasConceptScore W2953682493C126322002 @default.
• W2953682493 hasConceptScore W2953682493C143998085 @default.
• W2953682493 hasConceptScore W2953682493C168563851 @default.
• W2953682493 hasConceptScore W2953682493C203092338 @default.
• W2953682493 hasConceptScore W2953682493C207103383 @default.

• next